Militia Capital Partners LP Takes $816,000 Position in PROCEPT BioRobotics Corporation $PRCT

Key Points

• Militia Capital Partners LP acquired 14,000 shares of PROCEPT BioRobotics, valued at approximately $816,000, highlighting institutional interest in the company.
• PROCEPT BioRobotics shares have seen a positive trend with a 48.3% increase in revenue year-over-year, although the company continues to report negative earnings per share (EPS).
• Research analysts have mixed views on PROCEPT, with price targets ranging from $58.00 to $73.22, indicating a consensus rating of "Moderate Buy" for the stock.

Militia Capital Partners LP acquired a new position in PROCEPT BioRobotics Corporation (NASDAQ:PRCT - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 14,000 shares of the company's stock, valued at approximately $816,000.

Other large investors have also recently bought and sold shares of the company. Osterweis Capital Management Inc. boosted its holdings in PROCEPT BioRobotics by 98.0% during the first quarter. Osterweis Capital Management Inc. now owns 173,735 shares of the company's stock valued at $10,122,000 after acquiring an additional 85,990 shares during the period. Rhumbline Advisers boosted its holdings in PROCEPT BioRobotics by 5.0% during the first quarter. Rhumbline Advisers now owns 64,373 shares of the company's stock valued at $3,750,000 after acquiring an additional 3,077 shares during the period. Intech Investment Management LLC boosted its holdings in PROCEPT BioRobotics by 54.4% during the first quarter. Intech Investment Management LLC now owns 28,389 shares of the company's stock valued at $1,654,000 after acquiring an additional 10,002 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in PROCEPT BioRobotics by 9.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 153,158 shares of the company's stock valued at $8,923,000 after acquiring an additional 13,767 shares during the period. Finally, Dynamic Technology Lab Private Ltd bought a new stake in PROCEPT BioRobotics during the first quarter valued at about $336,000. 89.46% of the stock is currently owned by institutional investors.

PROCEPT BioRobotics Price Performance

NASDAQ:PRCT traded down $1.41 during mid-day trading on Wednesday, hitting $38.17. The company's stock had a trading volume of 374,444 shares, compared to its average volume of 1,016,968. The company has a current ratio of 9.21, a quick ratio of 7.86 and a debt-to-equity ratio of 0.13. The company has a market capitalization of $2.12 billion, a price-to-earnings ratio of -24.67 and a beta of 1.03. PROCEPT BioRobotics Corporation has a fifty-two week low of $36.90 and a fifty-two week high of $103.81. The stock has a fifty day moving average of $46.02 and a 200-day moving average of $53.34.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.06. The firm had revenue of $79.18 million for the quarter, compared to analysts' expectations of $75.67 million. PROCEPT BioRobotics had a negative net margin of 30.60% and a negative return on equity of 23.73%. The company's quarterly revenue was up 48.3% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.50) earnings per share. As a group, equities analysts forecast that PROCEPT BioRobotics Corporation will post -1.75 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

PRCT has been the subject of a number of recent analyst reports. Piper Sandler decreased their price target on shares of PROCEPT BioRobotics from $80.00 to $55.00 and set an "overweight" rating for the company in a report on Thursday, August 7th. Wall Street Zen upgraded shares of PROCEPT BioRobotics from a "sell" rating to a "hold" rating in a report on Saturday, August 9th. Stephens assumed coverage on shares of PROCEPT BioRobotics in a research report on Wednesday, July 9th. They set an "overweight" rating and a $70.00 price objective for the company. Wells Fargo & Company cut their price objective on shares of PROCEPT BioRobotics from $75.00 to $58.00 and set an "overweight" rating for the company in a research report on Thursday, August 7th. Finally, Oppenheimer raised shares of PROCEPT BioRobotics from a "market perform" rating to an "outperform" rating and set a $60.00 price objective for the company in a research report on Tuesday, September 2nd. Seven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, PROCEPT BioRobotics currently has an average rating of "Moderate Buy" and an average price target of $70.00.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).